| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 6 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
| | | | 14 | | | |
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 30 | | | |
| | | | 35 | | | |
| | | | 39 | | |
Name
|
| |
Class
|
| |
Age
(as of April 24) |
| |
Position
|
|
Michael Henderson, M.D.
|
| |
I
|
| |
34
|
| | Chief Executive Officer and Director | |
Mark C. McKenna(2)(3)
|
| |
III
|
| |
44
|
| | Independent Chair of the Board | |
Jennifer Fox(1)(2)
|
| |
III
|
| |
52
|
| | Independent Director | |
Andrew Gottesdiener, M.D.(1)
|
| |
I
|
| |
33
|
| | Independent Director | |
Peter Harwin(1)
|
| |
I
|
| |
38
|
| | Independent Director | |
William (BJ) Jones, Jr.(2)(3)
|
| |
III
|
| |
60
|
| | Independent Director | |
Tomas Kiselak
|
| |
II
|
| |
37
|
| | Independent Director | |
Nimish Shah(3)
|
| |
II
|
| |
46
|
| | Independent Director | |
| | |
Year Ended
December 31, |
| | | | |||||||||
Fee Category
|
| |
2023
|
| |
2022
|
| | ||||||||
Audit Fees(1)
|
| | | $ | 1,828,500 | | | | | $ | 150,000 | | | | ||
Audit-Related Fees(2)
|
| | | | — | | | | | | — | | | | ||
Tax Fees(3)
|
| | | | — | | | | | | — | | | | ||
All Other Fees(4)
|
| | | | — | | | | | | — | | | | ||
Total Fees
|
| | | $ | 1,828,500 | | | | | $ | 150,000 | | | |
| |
Grant Date:
|
| | |
August 17, 2023
|
| |
| |
Number of shares of common stock
covered by the Non-Plan Option: |
| | | 100,000 | | |
| |
Exercise Price Per Share:
|
| | |
$23.60
|
| |
| |
Expiration Date:
|
| | |
August 17, 2033 (if this Proposal 3 is approved)
|
| |
| |
Vesting Schedule:
|
| | | Subject to the 2023 Plan, the Non-Plan Option vests monthly in thirty-six equal installments commencing on August 17, 2023, subject to his continued service to us through each applicable vesting date. | | |
| |
Stockholder Approval Contingency:
|
| | | The Non-Plan Option is not exercisable prior to approval of the issuance of shares of common stock pursuant to the Non-Plan Option by the Company’s stockholders. | | |
Board Diversity Matrix
(as of the date of this Proxy Statement) |
| | | | | | | | | | | | | ||||||||||||||||||
Total number of directors — 8
|
| | | | | | | | | | | | | | | | | | | | | | | ||||||||
Gender identity:
|
| |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did Not
Disclose Gender |
| | | | | ||||||||||||||
Directors
|
| |
1
|
| |
7
|
| | | | — | | | | | | — | | | | | | | ||||||||
Number of directors who identify in any of the categories below: | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
African American or Black
|
| |
—
|
| |
1
|
| | | | — | | | | | | — | | | | | | | ||||||||
Alaskan Native or Native American
|
| |
—
|
| |
—
|
| | | | — | | | | | | — | | | | | | | ||||||||
Asian
|
| |
—
|
| |
1
|
| | | | — | | | | | | — | | | | | | | ||||||||
Hispanic or Latinx
|
| |
—
|
| |
—
|
| | | | — | | | | | | — | | | | | | | ||||||||
Native Hawaiian or Pacific Islander
|
| |
—
|
| |
—
|
| | | | — | | | | | | — | | | | | | | ||||||||
White
|
| |
1
|
| |
5
|
| | | | — | | | | | | — | | | | | | | ||||||||
Two or More Races or Ethnicities
|
| |
—
|
| |
—
|
| | | | — | | | | | | — | | | | | | | ||||||||
LGBTQ+
|
| |
—
|
| | | | | |||||||||||||||||||||||
Did Not Disclose Demographic Background
|
| |
—
|
| | | | |
Name
|
| |
Audit
Committee |
| |
Compensation
Committee |
| |
Nominating
Committee |
|
Jennifer Fox
|
| |
Chair
|
| |
X
|
| | | |
Andrew Gottesdiener, M.D.
|
| |
X
|
| | | | | | |
Peter Harwin
|
| |
X
|
| | | | | | |
Michael Henderson, M.D.
|
| | | | | | | | | |
William (BJ) Jones, Jr.
|
| | | | |
X
|
| |
Chair
|
|
Tomas Kiselak
|
| | | | | | | | | |
Mark C. McKenna
|
| | | | |
Chair
|
| |
X
|
|
Nimish Shah
|
| | | | | | | |
X
|
|
# of Meetings in 2023
|
| |
4
|
| |
5
|
| |
2
|
|
NAME
|
| |
OPTION
AWARDS ($)(1)(2) |
| |
STOCK
AWARDS ($)(3) |
| |
FEES EARNED
OR PAID IN CASH ($) |
| |
TOTAL
($) |
| ||||||||||||
Peter Harwin
|
| | | $ | 642,823 | | | | | | — | | | | | $ | 25,750 | | | | | $ | 668,573 | | |
Jennifer Fox
|
| | | | — | | | | | $ | 381,323 | | | | | $ | 33,250 | | | | | $ | 414,573 | | |
Andrew Gottesdiener, M.D.
|
| | | $ | 642,823 | | | | | | — | | | | | $ | 23,750 | | | | | $ | 666,573 | | |
William (BJ) Jones, Jr.
|
| | | | — | | | | | $ | 381,323 | | | | | $ | 30,333 | | | | | $ | 411,656 | | |
Tomas Kiselak
|
| | | $ | 642,823 | | | | | | — | | | | | $ | 20,000 | | | | | $ | 662,823 | | |
Mark McKenna
|
| | | $ | 940,000 | | | | | | — | | | | | $ | 32,870 | | | | | $ | 972,870 | | |
Nimish Shah
|
| | | $ | 642,823 | | | | | | — | | | | | $ | 22,000 | | | | | $ | 664,823 | | |
Name
|
| |
Age
(as of April 24) |
| |
Position
|
| |||
Michael Henderson, M.D.(1)
|
| | | | 34 | | | |
Chief Executive Officer and Director
|
|
Carl Dambkowski, M.D.
|
| | | | 39 | | | | Chief Medical Officer | |
Jane Pritchett Henderson
|
| | | | 58 | | | | Chief Financial Officer | |
NAME AND PRINCIPAL
POSITION |
| |
YEAR
|
| |
SALARY
($) |
| |
BONUS
($)(2) |
| |
OPTIONS
($)(3) |
| |
STOCK
AWARDS ($)(4) |
| |
ALL OTHER
COMPENSATION ($)(5) |
| |
TOTAL
($) |
| | |||||||||||||||||||||||
Michael Henderson, M.D.
Chief Executive Officer
|
| | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||
| | | 2023 | | | | | $ | 564,833 | | | | | $ | 606,375 | | | | | $ | 7,500,000 | | | | | | — | | | | | | — | | | | | $ | 8,671,208 | | | | | | ||
| | | 2022(1) | | | | | $ | 145,833 | | | | | $ | 167,123 | | | | | | — | | | | | $ | 6,079,410 | | | | | $ | 56,750 | | | | | $ | 6,449,116 | | | | ||||
Carl Dambkowski, M.D.
Chief Medical Officer
|
| | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||
| | | 2023 | | | | | $ | 477,083 | | | | | $ | 393,750 | | | | | $ | 3,300,000 | | | | | | — | | | | | | — | | | | | $ | 4,170,833 | | | | ||||
| | | 2022(6) | | | | | $ | 176,250 | | | | | $ | 212,932 | | | | | | — | | | | | $ | 1,194,638 | | | | | | — | | | | | $ | 1,583,820 | | | | ||||
Jane Pritchett Henderson(7)
Chief Financial Officer
|
| | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||
| | | 2023 | | | | | $ | 469,311 | | | | | $ | 374,332 | | | | | $ | 3,300,000 | | | | | $ | 881,270 | | | | | | — | | | | | $ | 5,024,913 | | | |
NAME
|
| |
TARGET ANNUAL CASH BONUS
(% OF BASE SALARY) |
| |||
Michael Henderson, M.D.
|
| | | | 55% | | |
Carl Dambkowski, M.D.
|
| | | | 45% | | |
Jane Pritchett Henderson
|
| | | | 45% | | |
NAME
|
| |
2023 ANNUAL CASH
BONUS |
| |||
Michael Henderson, M.D.
|
| | | $ | 606,375 | | |
Carl Dambkowski, M.D.
|
| | | $ | 393,750 | | |
Jane Pritchett Henderson
|
| | | $ | 374,332 | | |
| | |
STOCK OPTIONS
|
| |
STOCK AWARDS
|
| | | | | | | | | | | | | ||||||||||||||||||||||||||||||
| | |
NUMBER OF
|
| |
NUMBER OF
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||
| | |
SECURITIES
|
| |
SECURITIES
|
| | | | | | | | | | | | | | | | | | | |
MARKET
|
| | | | | | | | | | | |||||||||||
| | |
UNDERLYING
|
| |
UNDERLYING
|
| | | | | | | | | | | | | | | | | | | |
VALUE OF
|
| | | | | | | | | | | |||||||||||
| | |
UNEXERCISED
|
| |
UNEXERCISED
|
| | | | | | | | | | | | | |
NUMBER OF
|
| |
SHARES
|
| | | | | | | | | ||||||||||||||||
| | |
OPTIONS
|
| |
OPTIONS
|
| |
OPTION
|
| |
OPTION
|
| |
SHARES
|
| |
THAT HAVE
|
| | | | | ||||||||||||||||||||||||||
| | |
EXERCISABLE
|
| |
UNEXERCISABLE
|
| |
EXERCISE
|
| |
EXPIRATION
|
| |
THAT HAVE
|
| |
NOT VESTED
|
| | | | | ||||||||||||||||||||||||||
NAME
|
| |
(#)
|
| |
(#)(1)
|
| |
PRICE
|
| |
DATE
|
| |
NOT VESTED
|
| |
($)
|
| | | | | ||||||||||||||||||||||||||
Michael Henderson, M.D.
|
| | | | — | | | | | | 398,512 | | | | | $ | 22.86 | | | | | | 12/18/2033 | | | | | | | | | | | | | | | | | | | ||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 726,276(2) | | | | | | 20,292,151 | | | | | | | ||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 215,533(3) | | | | | | 6,021,992 | | | | | | | ||||||||||
Carl Dambkowski, M.D.
|
| | | | — | | | | | | 175,345 | | | | | $ | 22.86 | | | | | | 12/18/2033 | | | | | | | | | | | | | | | | | | | ||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 90,745(4) | | | | | | 2,535,415 | | | | | | | ||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 126,597(5) | | | | | | 3,537,120 | | | | | | | ||||||||||
Jane Pritchett Henderson
|
| | | | — | | | | | | 175,345 | | | | | $ | 22.86 | | | | | | 12/18/2033 | | | | | | | | | | | | | | | | | | | ||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 206,871(6) | | | | | | 5,779,976 | | | | | | | | | | | | | | |
Name of Beneficial Owner
|
| |
Number of
Shares of Voting Common Stock Owned |
| |
Number of
Shares of Non-Voting Common Stock Owned |
| |
Total
Percentage Ownership(1) |
| |
Voting
Power(2) |
| ||||||||||||
Greater than 5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | | | |
Entities affiliated with Fairmount Funds Management LLC(3)
|
| | | | 2,048,647** | | | | | | 6,743,321 | | | | | | 17.4% | | | | | | 5.8%** | | |
Entities affiliated with Venrock Healthcare Capital Partners III, L.P.(4)
|
| | | | 1,750,000** | | | | | | 6,743,321 | | | | | | 16.8% | | | | | | 5.0%** | | |
Entities affiliated with FMR LLC (Fidelity)(5)
|
| | | | 5,018,880 | | | | | | — | | | | | | 9.9% | | | | | | 14.3% | | |
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.(6)
|
| | | | 2,527,901 | | | | | | — | | | | | | 5.0% | | | | | | 7.2% | | |
Entities affiliated with Deep Track Capital, LP(7)
|
| | | | 2,323,456 | | | | | | — | | | | | | 4.6% | | | | | | 6.6% | | |
Paragon(8)
|
| | | | 2,259,073 | | | | | | — | | | | | | 4.5% | | | | | | 6.4% | | |
Entities affiliated with RTW Investments, LP(9)
|
| | | | 2,142,592 | | | | | | — | | | | | | 4.2% | | | | | | 6.1% | | |
Entities affiliated with RA Capital(10)
|
| | | | 1,977,901 | | | | | | — | | | | | | 3.9% | | | | | | 5.6% | | |
Perceptive Xontogeny Venture Fund II,
LP(11) |
| | | | 1,977,901 | | | | | | — | | | | | | 3.9% | | | | | | 5.6% | | |
Name of Beneficial Owner
|
| |
Number of
Shares of Voting Common Stock Owned |
| |
Number of
Shares of Non-Voting Common Stock Owned |
| |
Total
Percentage Ownership(1) |
| |
Voting
Power(2) |
| ||||||||||||
Entities affiliated with AI Biotechnology LLC(12)
|
| | | | 1,940,364 | | | | | | — | | | | | | 3.8% | | | | | | 5.5% | | |
Named Executive Officers, Directors and Nominees:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Michael Henderson, M.D.(13)
|
| | | | 705,011 | | | | | | — | | | | | | 1.4% | | | | | | 2.0% | | |
Carl Dambkowski, M.D.(14)
|
| | | | 123,123 | | | | | | — | | | | | | * | | | | | | * | | |
Jane Pritchett Henderson(15)
|
| | | | 74,948 | | | | | | — | | | | | | * | | | | | | * | | |
Mark C. McKenna(16)
|
| | | | 11,111 | | | | | | — | | | | | | * | | | | | | * | | |
Peter Harwin(3)
|
| | | | 2,099,813** | | | | | | 6,743,321 | | | | | | 17.5% | | | | | | 6.0%** | | |
Jennifer Fox
|
| | | | — | | | | | | — | | | | | | * | | | | | | * | | |
Andrew Gottesdiener, M.D.
|
| | | | — | | | | | | — | | | | | | * | | | | | | * | | |
William (BJ) Jones, Jr.
|
| | | | — | | | | | | — | | | | | | * | | | | | | * | | |
Tomas Kiselak(3)
|
| | | | 2,099,813** | | | | | | 6,743,321 | | | | | | 17.5% | | | | | | 6.0%** | | |
Nimish Shah(4)
|
| | | | 1,750,000** | | | | | | 6,743,321 | | | | | | 16.8% | | | | | | 5.0%** | | |
All current executive officers and directors as a group (10 persons)(17)
|
| | | | 4,815,172 | | | | | | 13,486,642 | | | | | | 36.1% | | | | | | 13.7% | | |
Plan Category
|
| |
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
| |
Weighted
Average Exercise Price of Outstanding Options, Warrants and Rights(1) |
| |
Number of
Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in the First Column) |
| |||||||||
Equity compensation plans approved by stockholders(2)
|
| | | | 2,650,107 | | | | | $ | 21.49 | | | | | | 4,534,933 | | |
Plan Category
|
| |
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
| |
Weighted
Average Exercise Price of Outstanding Options, Warrants and Rights(1) |
| |
Number of
Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in the First Column) |
| |||||||||
Total
|
| | | | 2,650,107 | | | | | $ | 21.49 | | | | | | 4,534,933 | | |
|
PARTICIPANT
|
| |
SERIES A
PREFERRED UNITS |
| |
CASH
PURCHASE PRICE |
| ||||||
Entities affiliated with Fairmount
|
| | | | 10,000,000 | | | | | $ | 10,000,000 | | |
Entities affiliated with Venrock
|
| | | | 10,000,000 | | | | | $ | 10,000,000 | | |
PARTICIPANT
|
| |
SERIES B
PREFERRED UNITS |
| |
CASH
PURCHASE PRICE |
| ||||||
Entities affiliated with Fairmount
|
| | | | 7,565,304 | | | | | $ | 25,000,000.99 | | |
Entities affiliated with Venrock
|
| | | | 7,565,304 | | | | | $ | 25,000,000.99 | | |
PARTICIPANT
|
| |
COMMON
STOCK |
| |
CASH
PURCHASE PRICE |
| ||||||
Entities affiliated with Fairmount
|
| | | | 2,941,176 | | | | | $ | 49,999,992 | | |
Entities affiliated with Venrock
|
| | | | 1,750,000 | | | | | $ | 29,750,000 | | |